Tenax Therapeutics Inc - TENX Expected earnings per share growth for next year

Corporate company logo of tenaxthera.com (TENX)

Tenax Therapeutics (TENX) is creating a unique environment for pulmonary hypertension therapy by tying clinics to its proprietary protocols. The consensus estimate for net profit growth reflects current market adaptation, where the latest parameter stands at 5.80. However, the absence of sales coupled with Phase III trial expenses is driving up costs. Business stability relies on the advancement of new cardiology drugs within US laboratories.

TENX: Tenax Therapeutics Inc. Expected earnings per share trend next year 07/04/2022 - 11/16/2026

Tenax Therapeutics, Inc. - analytical breakdowns and key metrics (TENX)

Basic company analysis:TENX, Tenax Therapeutics, Inc
Core merchandise of tenaxthera.com

For Tenax Therapeutics (TENX), the estimated growth in net income per share for the coming year reflects market expectations regarding the success of its heart failure medications. This indicator measures the percentage change in projected EPS, synthesizing analyst consensus estimates for future cash flows. The metric's trend captures the capitalization of scientific achievements and the company's ability to monetize clinical trial results.